Aardvark Therapeutics, Inc. (AARD): Total Assets
$117.18M
As of 2025-12-31
$81.46M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $117.18M | +51.2% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $77.51M | n/a | 2026-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $117.18M | +51.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare AARD, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗